Your session is about to expire
← Back to Search
NEXI-002 T Cells for Multiple Myeloma
Study Summary
This trial is being done to test the safety and effectiveness of a new experimental treatment for multiple myeloma called NEXI-002 T cell product. The treatment involves receiving a single infusion of the NEXI-002 T cell product after undergoing lymphodepleting therapy.
- Multiple Myeloma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
In how many places is this research being conducted?
"There are a total of 6 sites where this study is taking place. They are situated in Detroit, Boston, Orlando and other cities. To reduce the amount of travelling required, patients should select the site which is closest to them."
What is the total number of people enrolled in this trial?
"As stated in the inclusion criteria, 22 participants are required for this study. These volunteers can come from various locations, but must meet the specific prerequisites set out by the research team. For example, patients at Karmanos Cancer Institute in Detroit, Michigan and Dana-Farber Cancer Institute in Boston, Massachusetts are eligible to participate."
Are volunteers still needed for this research project?
"That is accurate. The clinical trial, which began recruiting on August 17th 2020, as indicated by the listing on clinicaltrials.gov, is still in need of 22 patients at 6 different locations."
Share this study with friends
Copy Link
Messenger